Page 6,504«..1020..6,5036,5046,5056,506..6,5106,520..»

Local stroke survivor talks amazing recovery and determination

Posted: Published on September 11th, 2012

Local stroke survivor talks amazing recovery and determination Local stroke survivor talks amazing recovery and determination Updated: Monday, September 10 2012 12:50 PM EDT2012-09-10 16:50:10 GMT The Chicago White Sox paid special tribute to a number of local stroke survivors this weekend, as part of a campaign to raise awareness about the nation's third leading cause of death. The Chicago White Sox paid special tribute to a number of local stroke survivors this weekend, as part of a campaign to raise awareness about the nation's third leading cause of death. First Lady Michelle Obama stopped by Dr. Oz's NYC studios to talk about her fight against childhood obesity, and to show how the first family gets their exercise. Dr. Oz explains. First Lady Michelle Obama stopped by Dr. Oz's NYC studios to talk about her fight against childhood obesity, and to show how the first family gets their exercise. Dr. Oz explains. Updated: Sunday, September 9 2012 6:00 PM EDT2012-09-09 22:00:16 GMT The number of people with West Nile virus in Lake County now stands at five according to the county's Health Department. The number of people with West Nile virus in Lake County now stands at five according to … Continue reading →

Comments Off on Local stroke survivor talks amazing recovery and determination

Clinical trials grow in Chattanooga area

Posted: Published on September 11th, 2012

Seth Carpenter, 5, jokes with volunteer Trent Whicker while playing video games at Erlanger Health System. Seth has been in treatment for leukemia during the last 19 months and it is currently in remission. A device that retrieves blood clots from the brain after a stroke, radiation delivered immediately after surgery for breast cancer and the latest leukemia treatment for children -- those are just a few of the devices and clinical trials undergoing testing in Chattanooga area hospitals. Once primarily done only in large teaching hospitals, in the last several decades research has shifted and doctors and clinicians now conduct clinical trials in most hospitals across the United States. On its website, which tracks clinical trials around the world, the National Institutes of Health list more than 6,000 trials in Tennessee, with about 700 of those in Chattanooga. Of the three local hospitals, Erlanger Health System conducts the most trials, with more than 200 ongoing, but officials at Memorial Health Care System and Parkridge Medical Center said their hospitals also are engaged in clinical trials. "I think we've seen the community of physicians becoming increasingly engaged in clinical research," said Dr. Colleen Schmitt, the medical director who heads up … Continue reading →

Comments Off on Clinical trials grow in Chattanooga area

Biomaterials Executive, Arthur J. Coury, PhD, Joins InVivo Therapeutics’ Business Advisory Board

Posted: Published on September 11th, 2012

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- InVivo Therapeutics Holdings Corp. (OTC/BB: NVIV), a developer of groundbreaking technologies for thetreatment of spinal cord injuries(SCI) and neurotrauma conditions, today announced that Arthur J. Coury, PhD, has joined the company as an advisor to the CEO. Dr. Courys focus on polymeric biomaterials for medical products such as implantable devices, hydrogel-based devices and drug delivery systems will bring critical expertise to InVivo as the company awaits approval to begin human studies. Dr. Courys experience and leadership has led to FDA approval of multiple hydrogel products, and has been drawn from his positions as Senior Research Chemist at General Mills, Inc.; Director, Polymer Technology and Research Fellow at Medtronic, Inc.; Vice President, Research and Chief Scientific Officer at Focal, Inc.; Vice President, Biomaterials Research at Genzyme Corporation; and most recently, his work as a consultant. Dr. Coury holds over fifty distinct patents and has published and presented widely in the field of biomaterials. In addition, Dr. Courys professional service to his field includes serving as Chair of the Minnesota Section of the American Chemical Society; as President for the Society for Biomaterials, USA; and as President for the American Institute for Medical and Biological Engineering (AIMBE). His recent … Continue reading →

Posted in Spinal Cord Injury Treatment | Comments Off on Biomaterials Executive, Arthur J. Coury, PhD, Joins InVivo Therapeutics’ Business Advisory Board

Florida Brain-Injury Center Fights Order to Move Patients

Posted: Published on September 11th, 2012

By David Armstrong - 2012-09-10T10:00:00Z A Florida brain-injury facility accused of abusive and substandard practices is fighting a state order to move out scores of patients, saying regulators are overstepping their authority. The Florida Institute for Neurologic Rehabilitation, located 50 miles southeast of Tampa in rural Wauchula, told the state Friday that it would not begin the process of discharging any patients until a judge hears an appeal it filed on Aug. 28. That action, before the Division of Administrative Hearings, alleges state regulators exceeded their authority in ordering the removal of patients and acted in an arbitrary and capricious way. The dispute stems from a surprise inspection last month by three state agencies. Regulators moved in after Bloomberg News reported on dozens of cases of alleged abuse and neglect at the for-profit facility, known as FINR. Patients families or state agencies have accused the centers staffers of abuse or care lapses in at least five residents deaths since 1998, two of them in the last two years. Michelle Dahnke, a spokeswoman for the states Agency for Health Care Administration, which was sent FINRs response, declined to comment. State investigators determined FINR was breaching its license by treating 50 patients … Continue reading →

Posted in Brain Injury Treatment | Comments Off on Florida Brain-Injury Center Fights Order to Move Patients

Bridie Manor Celebrates 25 Years With MS Awareness Poker Run

Posted: Published on September 11th, 2012

By: Joleene DesRosiers Moody OSWEGO, NY Larry Lombardo has been in business for 25 years. A week after Bridie Manor opened its doors, Lombardo was diagnosed with a chronic, progressive disease that affects the central nervous system, brain, spinal cord and optic nerves: Multiple Sclerosis. Larry Lombardo beats the odds every day. He plays piano regularly. Now hes ready to celebrate a dual milestone that has more than opened his eyes to a world where blood, sweat and tears are much more than a metaphor. Im 58-years-old and Ive had MS for over two decades, he said. Ive owned this place just as long. What better way to celebrate our anniversary together than educating people in our community about this disease? Weve reached out to Multiple Sclerosis Resources of New York to help us with a fundraiser that will do just that. Multiple Sclerosis Resources of New York of East Syracuse has teamed up with OswegoCountyToday.com to spearhead the event. On Saturday, October 6, close to 250 people are expected to take part in a Poker Run. Participating business are: Thrifty Shopper The Press Box Murdocks Bicycles and Sports Cider Moon Coffee and Caf Marias Family Restaurant Harbor Towne Gifts … Continue reading →

Posted in MS Treatment | Comments Off on Bridie Manor Celebrates 25 Years With MS Awareness Poker Run

Moffitt researchers say race affect likelihood of finding suitable stem cell donor

Posted: Published on September 11th, 2012

Public release date: 11-Sep-2012 [ | E-mail | Share ] Contact: Kim Polacek kim.polacek@moffitt.org 813-745-7408 H. Lee Moffitt Cancer Center & Research Institute Researchers at Moffitt Cancer Center and colleagues have published a study describing the greater difficulty in finding matched, unrelated donors for non-Caucasian patients who are candidates for hematopoietic cell transplantation (HCT). The study appeared in the August issue of Bone Marrow Transplantation. The success of HCT depends on finding cell donors who are closely matched genetically; as the degree of mismatching increases, the success of unrelated donor HCT falls accordingly. A patient's ideal donor is a genetically matched sibling. The search for a perfectly matched donor for all groups takes time and affects the progression to transplantation. The National Marrow Donor Program estimates that the genetically matched donor rate is 90 percent for Caucasian patients, 70 percent for Hispanics and Asians, and 60 percent for those of African ancestry. "Using unrelated adult donors to facilitate HCT has provided major opportunities for patients without a matched sibling donor. In fact, the rate of unrelated donors now exceeds the rate of related donor HCT," said Joseph Pidala, M.D., M.S., assistant member of Moffitt's Blood & Marrow Transplant Department and … Continue reading →

Posted in Stem Cell Research | Comments Off on Moffitt researchers say race affect likelihood of finding suitable stem cell donor

Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the "Achilles' Heel" of Cancer

Posted: Published on September 11th, 2012

Newswise Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer stem cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team evaluated human tissue … Continue reading →

Posted in Stem Cell Research | Comments Off on Researchers Reveal a Chemotherapy-Resistant Cancer Stem Cell as the "Achilles' Heel" of Cancer

Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

Posted: Published on September 11th, 2012

Public release date: 10-Sep-2012 [ | E-mail | Share ] Contact: Mount Sinai Press Office newsmedia@mssm.edu 212-241-9200 The Mount Sinai Hospital / Mount Sinai School of Medicine Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer "stem" cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers … Continue reading →

Posted in Stem Cell Research | Comments Off on Researchers reveal a chemo-resistant cancer stem cell as cancer's 'Achilles' heel'

Chemotherapy-resistant cancer stem cell could be 'Achilles' heel' of cancer

Posted: Published on September 11th, 2012

ScienceDaily (Sep. 10, 2012) Scientists at Mount Sinai School of Medicine have discovered a subpopulation of cells that display cancer stem cell properties and resistance to chemotherapy, and participate in tumor progression. This breakthrough could lead to the development of new tests for early cancer diagnosis, prognostic tests, and innovative therapeutic strategies, as reported in Cancer Cell. Resistance to chemotherapy is a frequent and devastating phenomenon that occurs in cancer patients during certain treatments. Unfortunately, tumors that initially respond to chemotherapy eventually become resistant to it, contributing to tumor progression and death. The study reveals that these new cancer "stem" cells, which have not been differentiated into more specific cell types, are capable of multiplying despite being exposed to chemotherapy, while differentiated cells die. Led by Carlos Cordon-Cardo, MD, PhD, Chair of Pathology, and Josep Domingo-Domenech, MD, PhD, Assistant Professor of Pathology at Mount Sinai, the research team generated cellular models of drug resistance by treating prostate tumor cell lines with increasing doses of the common chemotherapy drugs, including docetaxel. They identified a cell population expressing markers of embryonic development. In addition, these cells displayed cancer stem cell functions, including the capacity to initiate tumor cell growth. Next, the team … Continue reading →

Posted in Stem Cell Research | Comments Off on Chemotherapy-resistant cancer stem cell could be 'Achilles' heel' of cancer

New genetic mechanism for controlling blood cell development and blood vessel integrity found

Posted: Published on September 11th, 2012

Public release date: 10-Sep-2012 [ | E-mail | Share ] Contact: Dian Land dj.land@hosp.wisc.edu 608-261-1034 University of Wisconsin-Madison MADISON The protein GATA2 is known as a "master regulator" of blood cell development. When a mutation occurs in the gene that makes GATA2, serious blood diseases such as acute myeloid leukemia can result. Zooming in on the GATA2 gene, UW-Madison researchers and their collaborators at the National Institutes of Health (NIH) have discovered unexpectedly that a small DNA sequence drives this powerful master regulator. The sequence plays an essential role in controlling GATA2 production and generating self-renewing blood stem cells responsible for the earliest steps in the development of blood cells of all kindsred cells to transport oxygen and white cells to fight infection. The researchers also found that the DNA sequence, which they call the +9.5 GATA2 switch site, ensures that blood vessels function properly to prevent hemorrhaging. Until now, GATA2 had not been implicated in blood vessel integrity. The study appears in The Journal of Clinical Investigation (online Sept. 10, 2012). Although the study was performed in mice, it should have significant clinical relevance, particularly to physicians and scientists aiming to understand certain types of leukemia and related disorders … Continue reading →

Comments Off on New genetic mechanism for controlling blood cell development and blood vessel integrity found

Page 6,504«..1020..6,5036,5046,5056,506..6,5106,520..»